BIIB
Biogen IncNASDAQ
Healthcare • Drug Manufacturers - General
Factor tilt: Large-Cap Blend
$248.35+1.81%
Close Nov 6, 2026
- Market cap
- $36.67B
- 1 month
- +13.7%
- 3 months
- +19.9%
- 1 year
- +61.9%
- 52-week range
- $155.51$254.46
- Dividend
- No dividends on record
- Short interest
- 3.7% of float5.5M shares · settled Oct 15, 2026 · -7.8% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $10.3B
- Net income
- —
- Free cash flow
- $2.34B
- Book value
- $18.92B
- Total debt
- $7.8B
- P/E
- —
- Price / sales
- 3.6×
- Price / book
- 1.9×
- FCF yield
- +6.4%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an
Read more
etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- Website
- biogen.com
- Headquarters
- Cambridge, MA, United States
- Employees
- 7,500
- Listed
- Sep 16, 1991
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 30, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Oct 28, 2026 | $2.8B | +14.2% | 73.3% | -$9.0M | -$20.6M |
| Jun 2026filed Jul 29, 2026 | $2.7B | +3.4% | 56.9% | $318.1M | $97.5M |
| Mar 2026filed Apr 29, 2026 | $2.5B | +1.9% | 73.3% | $397.4M | $319.5M |
| Dec 2025filed Feb 6, 2026 | $2.3B | -7.1% | 78.2% | -$57.0M | -$48.4M |
| Sep 2025filed Oct 30, 2025 | $2.5B | -0.4% | 64.3% | $613.8M | $466.5M |
| Jun 2025filed Jul 31, 2025 | $2.6B | +7.3% | 64.2% | $588.1M | $634.8M |
| Mar 2025filed May 1, 2025 | $2.4B | +6.1% | 76.2% | $732.6M | $240.5M |
| Dec 2024filed Feb 12, 2025 | $2.5B | +2.9% | 76.2% | $509.0M | $266.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 6, 2026 | $9.8B | +1.4% | 70.5% | $1.9B | $1.3B |
| Dec 2024filed Feb 12, 2025 | $9.7B | -1.6% | 76.1% | $2.5B | $1.6B |
| Dec 2023filed Feb 14, 2024 | $9.8B | -3.3% | 74.2% | $2.1B | $1.2B |
| Dec 2022filed Feb 15, 2023 | $10.2B | -7.4% | 77.6% | $2.9B | $3.0B |
| Dec 2021filed Feb 3, 2022 | $11.0B | -18.3% | 80.8% | $2.8B | $1.6B |
| Dec 2020filed Feb 3, 2021 | $13.4B | -6.5% | 86.6% | $4.6B | $4.0B |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched BIIB. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
5,500,386 shares short
-465,506 shares (-7.8%) vs Sep 30, 2026
3.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
5,965,892 shares short
+148,095 shares (+2.5%) vs Sep 15, 2026
4.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
5,817,797 shares short
+91,166 shares (+1.6%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
5,726,631 shares short
+536,076 shares (+10.3%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
5,190,555 shares short
-263,346 shares (-4.8%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
5,453,901 shares short
-545,232 shares (-9.1%) vs Jul 15, 2026
3.7% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind BIIB’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
3 for 1 · forward split
Effective Jan 18, 2001
Each 1 pre-split share becomes 3 post-split shares.
Source: EODHD
2 for 1 · forward split
Effective Dec 21, 1999
Each 1 pre-split share becomes 2 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if BIIB is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
140 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Nov 3, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
1,047 filers reported a long position in BIIB for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
60.1%
of the 142.4M shares 13-F filers reported
Moves vs Q1 2026
9 added0 trimmed
1 not comparable
Net shares held
+8.8%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $3.9B · 18.2M shares | 18.2M | +42.2% |
| 2 | BlackRock, Inc. | $3.5B · 16M shares | 16M | +0.1% |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | $3.3B · 15.2M shares | 15.2M | +2.7% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $2.1B · 9.7M shares | 9.7M | +1.2% |
| 5 | STATE STREET CORP | $1.6B · 7.3M shares | 7.3M | +2.5% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | $1.4B · 6.6M shares | 6.6M | +1.1% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $957.9M · 4.4M shares | 4.4M | +2.5% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | $673.6M · 3.1M shares | 3.1M | +5.3% |
| 9 | NORGES BANK | $557.4M · 2.6M shares | 2.6M | — |
| 10 | MORGAN STANLEY | $521M · 2.4M shares | 2.4M | +11.1% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of BIIB file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 6, 2026 | FMR LLC13G · passive · amended | 12.4% |
| Apr 29, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 7.48% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for BIIB
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.